TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06784310

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medically Tailored Meals
Description: Dare to Care will provide meals each week for 12 weeks tailored for comorbidities. Meals will be provided to both the adult and the child(ren). Meals have been developed with a Registered Dietitian and have been approved through Food Is Medicine Coalition (FMIC). Meals are delivered via Door Dash each week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Grocery Prescription
Description: Instacart Fresh Funds (for those that need delivery) or Kroger Grocery Rx cards will be issued to each participant per month to be spent on eligible healthy food items (lean protein, lean dairy, fruits, vegetables, eggs, and nuts). For each participating child in the household, they will receive additional funds/per child loaded on their grocery Rx card

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medically Tailored Meals and Grocery Prescription
Description: will receive both tailored MTM meals per week for adult and child(ren) and the GP monthly grocery funds

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Counseling
Description: 30 minutes per week of nutrition counseling and assistance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Counseling
Description: 30 minutes per week of nutrition counseling and assistance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Counseling
Description: 30 minutes per week of nutrition counseling and assistance.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional Counseling
Description: 30 minutes per week of nutrition counseling and assistance.
Study: NCT06786169

Intervention type: OTHER
Intervention: psychological stress status
Description: The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 were categorized as the stressed group.

Intervention type: OTHER
Intervention: psychological stress status
Description: The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 were categorized as the stressed group.

Intervention type: OTHER
Intervention: psychological stress status
Description: The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 were categorized as the stressed group.
Study: NCT06784869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scaling and root surface debritment
Description: Patients with 4-6 mm pocket depth were participated in this study; clinical periodontal parameters (BOP, PLI, PPD, CAL) were recorded at the baseline visit. To ensure sampling accuracy, From the site two papers with GCF were sampled. Following sample collecting for GCF, Every patient received comprehensive mouth supragingival scaling with an ultrasonic scaler (WoodpEEKer® UDS-K) along with dental hygiene recommendations. One week later, the sites were irrigated with normal saline after being scaled and root planed (ScRp) with Gracey curette. Following completion of subgingival instrumentation, each patient returned to the clinic following 1 and 3 months for periodontal parameter recording and GCF collection. Throughout these sessions, every patient received reinstruction to engage in self-oral hygiene practices.
Study: NCT05279313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centanafadine Hydrochloride
Description: Capsule
Study: NCT05532904

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Personalized multidisciplinary day-hospital intervention
Description: This 6-week program of care will include:~* group education sessions including a psycho-education component (1 session / week)~* a personalized exercise training protocol (from 1 session of supervision to 3 sessions of guided exercise per week) adapted to the results of the VO2max exercise test.~* if dysfunctional health beliefs are identified (SSD-12 score ≥ 26): a group protocol of cognitive and behavior therapy (2 sessions per week, including at least 1 in person).~* if cognitive complaints and/or neuropsychological impairment: a cognitive remediation protocol (1 group session plus 2 home sessions per week)
Study: NCT04878354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tree SLIT-tablet
Description: Sublingual allergy immunotherapy tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SLIT-tablet
Description: Placebo
Study: NCT06272487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilebesiran
Description: Zilebesiran administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered by SC injection
Study: NCT06382064

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biweekly replacement contact lenses
Description: Biweekly replacement reusable contact lenses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: One week replacement contact lenses
Description: One week replacement reusable contact lenses.
Study: NCT05372185

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VA Coordinated Anxiety Learning and Management- Substance Use Version
Description: VA Coordinated Anxiety Learning and Management- Substance Use Version (VA CALM-S) is a cognitive behavior therapy (CBT) program that employs computer assistance to empower providers to deliver CBT with high fidelity. The computer program guides both providers and patients in a course of CBT, and in this study the content will focus on using transdiagnostic treatment elements to address co-occurring anxiety and substance use disorders.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Veterans will engage in VA care using the standard procedures of their facility.
Study: NCT05678712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Access to CGM data (Dexcom G6)
Description: Acces to CGM data (not blinded CGM)
Study: NCT05891769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18Fluorocholine
Description: 18F Fluorocholine 5 mCi ± 20% administered intravenously.
Study: NCT05671159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: A supplementary blood sample will be taken including a 5mL EDTA tube and a paxgene tube

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: A supplementary blood sample will be taken including a 5mL EDTA tube and a paxgene tube
Study: NCT04973709

Intervention type: DIAGNOSTIC_TEST
Intervention: Confussion assessment method (CAM)
Description: Participants enrolled in the Delirium group according to the CAM.

Intervention type: DIAGNOSTIC_TEST
Intervention: Confussion assessment method (CAM)
Description: Participants enrolled in the Delirium group according to the CAM.

Intervention type: DIAGNOSTIC_TEST
Intervention: Dementia diagnosis
Description: Participants enrolled in the Dementia group according to the CDR scores and MMSE scores and DSM4/5 criteria

Intervention type: DIAGNOSTIC_TEST
Intervention: Dementia diagnosis
Description: Participants enrolled in the Dementia group according to the CDR scores and MMSE scores and DSM4/5 criteria
Study: NCT06099769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: mouth once daily (160 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: mouth once daily (160 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: mouth once daily 300-mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPC
Description: The treating physician must select from one of the following regimens:~* Eribulin 1.4 mg/m2 IV Day 1 and Day 8 in a 21-day cycle~* Capecitabine 1000-1250 mg/m2 twice daily, orally Day 1-14 in a 21-day cycle~* Paclitaxel 80 mg/m2 IV Day 1, Day 8 in a 21-day cycle~* Carboplatin AUC 6 IV Day 1 in a 21-day cycle~* Carboplatin AUC 2 IV Day 1, Day 8 and Day 15 in a 21-day cycle
Study: NCT06463665

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Olvimulogene nanivacirepvec
Description: Olvi-Vec is an engineered oncolytic vaccinia virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Olvimulogene nanivacirepvec
Description: Olvi-Vec is an engineered oncolytic vaccinia virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Olvimulogene nanivacirepvec
Description: Olvi-Vec is an engineered oncolytic vaccinia virus

Intervention type: DRUG
Group type: OTHER
Intervention: Platinum chemotherapy: carboplatin or cisplatin
Description: Administered according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum chemotherapy: carboplatin or cisplatin
Description: Administered according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum chemotherapy: carboplatin or cisplatin
Description: Administered according to local practice.

Intervention type: DRUG
Group type: OTHER
Intervention: Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC
Description: Administered according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC
Description: Administered according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC
Description: Administered according to local practice.

Intervention type: DRUG
Group type: OTHER
Intervention: Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab
Description: Administered according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab
Description: Administered according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab
Description: Administered according to local practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Administered according to local practice.

Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: Administered according to local practice.
Study: NCT06467084

Intervention type: DRUG
Group type: OTHER
Intervention: KVD900 75 mg
Description: KVD900 Tablet 75 mg (1 x 75 mg)

Intervention type: DRUG
Group type: OTHER
Intervention: KVD900 150 mg
Description: KVD900 Tablet 150 mg (2 x 75 mg)

Intervention type: DRUG
Group type: OTHER
Intervention: KVD900 300 mg
Description: KVD900 Tablet 300 mg (1 x 300 mg)
Study: NCT05030038

Intervention type: BIOLOGICAL
Intervention: Fecal swab collection
Description: Participants will collect fecal sample at home and either mail in the sample, or drop it off at the lab

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Participants will have approximately 1 teaspoon of blood withdrawn from a vein, for research, on 2 different occasions. The total amount of blood withdrawn during the study will be approximately 2 teaspoons.
Study: NCT05736744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MgSO4
Description: The patients will be pretreated with magnesium sulphate infusion (30 mg kg-1, total volume 100 ml, infusion rate 5 ml min-1) 20 min. before induction of anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cis-Atracurium
Description: Cis-Atracurium will be administered at 0.1-0.15 mg/kg IV bolus for intubation and maintenance at a dose of 0.03 mg/kg iv on fixed intervals.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cis-Atracurium
Description: Cis-Atracurium will be administered at 0.1-0.15 mg/kg IV bolus for intubation and maintenance at a dose of 0.03 mg/kg iv on fixed intervals.
Study: NCT05550207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-07 (meloxicam-rizatriptan)
Description: AXS-07 tablets, taken orally for the acute treatment of migraine
Study: NCT05336344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENCODE
Description: a cognitive behavioral intervention for family caregivers to improve pain management skills and overall coping
Study: NCT06241118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Description: Pharmaceutical form: Various Topical formulation Route of administration: Topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Description: Pharmaceutical form: Various Topical formulation Route of administration: Topical

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical corticosteroids
Description: Pharmaceutical form: Various Topical formulation Route of administration: Topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus or pimecrolimus
Description: Pharmaceutical form: Various Topical formulation Route of administration: Topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus or pimecrolimus
Description: Pharmaceutical form: Various Topical formulation Route of administration: Topical

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical tacrolimus or pimecrolimus
Description: Pharmaceutical form: Various Topical formulation Route of administration: Topical
Study: NCT05188508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive pembrolizumab 200mg IV on day 1 (± 3days) of each cycle. Pembrolizumab will continue every 21 days (± 3 days) throughout the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive pembrolizumab 200mg IV on day 1 (± 3days) of each cycle. Pembrolizumab will continue every 21 days (± 3 days) throughout the trial.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Olaparib and Temozolomide
Description: Olaparib and temozolomide will begin on cycle 3 day 1 and continue through cycle 11. Olaparib will be dosed 200mg orally twice a day (bid) days 1-7 each cycle. Temozolomide 50 mg/m2 will be administered orally days 1-7 each cycle.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Olaparib and Temozolomide
Description: Olaparib and temozolomide will begin on cycle 3 day 1 and continue through cycle 11. Olaparib will be dosed 200mg orally twice a day (bid) days 1-7 each cycle. Temozolomide 50 mg/m2 will be administered orally days 1-7 each cycle.
Study: NCT06444724

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: APP
Description: Patients in the application group communicated via Line applications (APP group) with guidance on preparation before colonoscopy through video media.
Study: NCT06087614

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: DE-HyART
Description: The HSV delineation will be done for patients in arm 3 using baseline FMISO. The HSV will be contoured and adjusted according to the second FMISO scan done between the 4th - the 5th week of radiation treatment. A planning CT will also be repeated at the time for adjusting the HSV to account for temporal changes. The Biological Target Volume thus generated after adequate margins will be prescribed 30 Gy in 10 fractions over and above the standard fractination.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Arm
Description: The prescribed radiotherapy dose will be 70 Gy in 2 Gy per fraction daily. The elective volume will be treated with 50 Gy in 2 Gy per fraction daily till the first 5 weeks. The entire treatment will be delivered in a phased mannered using sequential planning.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin injection
Description: Concurrent chemotherapy, weekly Inj Cisplatin 40mg/m2. This will be given if clinically indicated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin injection
Description: Concurrent chemotherapy, weekly Inj Cisplatin 40mg/m2. This will be given if clinically indicated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin injection
Description: Concurrent chemotherapy, weekly Inj Cisplatin 40mg/m2. This will be given if clinically indicated

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Standard fractionation (Radiation Oncology preference)
Description: Standard institutional practice is detailed before starting the patient. Doses 66-70 Gy over 6-7 weeks
Study: NCT06783764

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PECS II block and transverse thoracic plane block
Description: will receive a combination of PECS II block and TTPB (injection of 10 ml 0.25% bupivacaine between pectoralis major and minor muscles and 10 ml between the pectoralis minor and serratus anterior muscles) at the third or the fourth rib, then 10 ml between the internal inter-costal muscles and the transversus thoracic muscle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: ESPB (30 ml of 0.25% bupivacaine injected deep to the erector spinae muscle at the transverse process of the fifth thoracic vertebrae)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine 0.25 % injection
Description: injection of 10 ml 0.25% bupivacaine between pectoralis major and minor muscles and 10 ml between the pectoralis minor and serratus anterior muscles) at the third or the fourth rib, then 10 ml between the internal inter-costal muscles and the transversus thoracic muscle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine 0.25 % injection
Description: 30 ml of 0.25% bupivacaine injected deep to the erector spinae muscle at the transverse process of the fifth thoracic vertebrae
Study: NCT06786208

Intervention type: DRUG
Intervention: Sunvozertinib
Description: sunvozertinb, a EGFR-TKI, 300mg QD oral
Study: NCT06785155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chatbot group
Description: Participants explored the topics using the AI chatbot platform.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: website assisted
Description: Participants explored the topics using the website platform
Study: NCT06785168

Intervention type: OTHER
Group type: OTHER
Intervention: Machine-based Resistance Training
Description: The participants will receive HF treatment as prescribed by cardiologists. If participants have any additional medical conditions, their existing medications or treatments should continue. They are also asked to maintain their usual physical activity, exercise routines, and dietary habits, without making changes outside of the study intervention. At the beginning, patients participating in resistance training should complete a pretest of one-repetition maximum (1-RM) to assess muscle strength, which will be used by a professional physical therapist to develop an individualized prescription. The specific movements are as follows: (1) leg press and (2) calf raise by Proxomed Compass 540 (Germany); (3) leg curl, (4) chest press, (5) push up, (6) seated row by HUR machine (US). During the 8 weeks, subjects will train 3 non-consecutive days/week with intensity 30%1-RM to 60% 1-RM, 3 sets/one excercise with 8-12 repetitions.
Study: NCT06786910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toothpaste with olive oil, betaine and xylitol
Description: Composition comprising olive oil, betaine and xylitol, formulated as a toothpaste to be delivered topically onto the oral cavity 3 times a day during 1 month.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Toothpaste without olive oil, betaine nor xyitol
Description: Toothpaste without olive oil, without betaine and without xylitol, with identical aspect and flavour to the intervention to use 3 times a day during 1 month.
Study: NCT06785181

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Active standing
Description: a session at resting state in supine position, a session during autonomic challenge obtained via active standing evoking reflex sympathetic activation, and a session of emotional elicitation via the administration of videos
Study: NCT06786195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-body vibration and Jumping
Description: The subjects were first asked to jump in place 20 times, as if they were jumping rope. Then, whole-body vibration was applied. While the participants stood upright on the whole-body vibration device, low-amplitude (1.2 mm) vibrations were applied at eight different frequencies (25, 27, 29, 31, 33, 35, 37, 39 Hz), each lasting for 10 seconds, with a 5-second rest period in between. The Achilles tendon will be percussed 10 times with an electronic reflex hammer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-body vibration and Jumping
Description: The subjects were first asked to jump in place 20 times, as if they were jumping rope. Then, whole-body vibration was applied. While the participants stood upright on the whole-body vibration device, low-amplitude (1.2 mm) vibrations were applied at eight different frequencies (25, 27, 29, 31, 33, 35, 37, 39 Hz), each lasting for 10 seconds, with a 5-second rest period in between. The Achilles tendon will be percussed 10 times with an electronic reflex hammer.
Study: NCT06781580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Esports Ergonomic Protocol
Description: The Esports Ergonomic Protocol is a six-week intervention designed to reduce the risk of repetitive strain injuries and enhance gaming performance for esports athletes. It includes an educational session on ergonomics, focusing on proper posture, body mechanics, and workstation setup. The protocol also incorporates warm-up and cool-down exercises to prevent strain and improve flexibility, as well as a postural rehabilitation program targeting the upper extremities and core muscles.~Participants will attend four in-person sessions at specified intervals for ergonomic risk assessments (using REBA) and gaming performance evaluations (using Kovaaks). The intervention also features online resources, including exercise tutorials and ergonomic tips, to support adherence and long-term implementation. Feedback will be collected through post-intervention surveys and an optional focus group to refine the protocol for future use in the esports community.